Drag a card by its title · ⚙ to size, swap or remove

The company

BlossomHill Therapeutics, Inc.

BLSM · Nasdaq

Health CareBiotechnology

We hold no 150-day reading for BLSM yet: it needs about 200 sessions of history. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation: not in the set
Weeks in an uptrend: —
Industry in uptrend: 18% -14 in 4 wk
Insider buys, 12 months: $50.4M
Insider sales, 12 months: $0
Officials’ trades on record: 0
Institutions holding: 0

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 0 weeks.

21 Apr – 20 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months9

Sale orders, 12 months0

Buyers · sellers8 · 0

Who	Did	Shares	Traded
Orbimed Advisors LlcDirector	bought	625,000at $16.00	10 Aug 2026filed 12 Aug 2026
Carl L. GordonDirector	bought	625,000at $16.00	10 Aug 2026filed 12 Aug 2026
Bihua ChenDirector, 10% owner	bought	312,500at $16.00	10 Aug 2026filed 10 Aug 2026
John P. SchmidDirector	bought	6,000at $16.00	10 Aug 2026filed 10 Aug 2026
Jason A. KeyesChief Financial Officer	bought	700at $16.00	10 Aug 2026filed 10 Aug 2026
Vincent Paul LiptakGeneral Counsel	bought	2,200at $16.00	10 Aug 2026filed 10 Aug 2026
Vincent Paul LiptakGeneral Counsel	bought	2,500at $15.80	7 Aug 2026filed 10 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders0

New · exited0 · 0

Reported value$0

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change

News

Biotech Stocks At 52-Week Highs - BlossomHill Therapeutics +18% On Positive Trial Data, Adaptive Biotechnologies, Illumina, CeriBell, Neogenfinanznachrichten.de · 17 Sep 2026 BlossomHill Therapeutics Shares Rise 4.4% After BH-30643 Trial Updateyahoo.com · 16 Sep 2026

Everyone who traded it

Bihua Chen Director, 10% owner · last 10 Aug 20261 · 0

Carl L. Gordon Director · last 10 Aug 20261 · 0

Cormorant Private Healthcare Fund Vi, Lp 10% owner · last 10 Aug 20261 · 0

Jason A. Keyes Chief Financial Officer · last 10 Aug 20261 · 0

Jingrong Jean Cui President and CEO · last 10 Aug 20260 · 0

John P. Schmid Director · last 10 Aug 20261 · 0

ORBIMED ADVISORS LLC Director · last 10 Aug 20261 · 0

Orbimed Capital Gp Viii Llc Director · last 10 Aug 20261 · 0

Sundeep Agrawal Director · last 10 Aug 20260 · 0

Vincent Paul Liptak General Counsel · last 10 Aug 20262 · 0

Yishan Li Executive Chairman · last 10 Aug 20260 · 0

Geoffrey Raymond Oxnard Chief Medical Officer · last 6 Aug 20260 · 0

Same industry

No other stock in its industry this week.

Government contracts

No federal award is tied to it.

From its SEC filings

No ratio computed from its SEC filings yet.

Analyst forecasts

No analyst forecasts yet.